ALK and neuroblastoma: Furthermore, relapsed neuroblastoma harbors increased somatic mutations, with enrichment of ALK-activating subclonal/clonal mutations compared to diagnostic tumors, with a frequency of 20% and rising as we sequence patient tumors and/or plasma more routinely at time of relapse6–9.